UMRX vs. CTNM, EPIX, CRMD, ENTA, NBTX, XOMA, VRCA, VNDA, INZY, and HOWL
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Contineum Therapeutics (CTNM), ESSA Pharma (EPIX), CorMedix (CRMD), Enanta Pharmaceuticals (ENTA), Nanobiotix (NBTX), XOMA (XOMA), Verrica Pharmaceuticals (VRCA), Vanda Pharmaceuticals (VNDA), Inozyme Pharma (INZY), and Werewolf Therapeutics (HOWL). These companies are all part of the "medical" sector.
Cogent Biosciences (NASDAQ:UMRX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Contineum Therapeutics has a net margin of 0.00% compared to Cogent Biosciences' net margin of -96.84%. Contineum Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.
26.4% of Cogent Biosciences shares are owned by institutional investors. 31.5% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Contineum Therapeutics had 7 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Contineum Therapeutics and 0 mentions for Cogent Biosciences. Contineum Therapeutics' average media sentiment score of 0.43 beat Cogent Biosciences' score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.
Contineum Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 81.23%. Given Contineum Therapeutics' higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Cogent Biosciences.
Contineum Therapeutics has lower revenue, but higher earnings than Cogent Biosciences.
Cogent Biosciences received 183 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 68.38% of users gave Cogent Biosciences an outperform vote.
Summary
Contineum Therapeutics beats Cogent Biosciences on 8 of the 12 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
